Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease

Informations projet

ADDIA

N° de convention de subvention: 674474

DOI 10.3030/674474

Projet clôturé

Date de signature de la CE 10 Juillet 2015

Date de début 1 Août 2015

Date de fin 31 Juillet 2019

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 4 998 625,00

Contribution de l’UE € 4 998 625,00

Coordonné par

AMONETA DIAGNOSTICS
France

Livrables

Documents, reports (2)

Letters and project updates to patient organisation Alzheimer Europe

AD patient organizations will be contacted to disseminate the project progress regarding AD diagnosis with the ADDIA assay to AD patients and their families, via announcements on patient organization’s websites and sending out letters.

Scientific papers prepared for peer-reviewed open access journals

Amoneta aims to raise the awareness, acceptance and support of the scientific and medical experts regarding the novel IVD assay for AD diagnosis:  Outcomes from the ADDIA project will be presented at international and national conferences.  Regular updates (in the form of abstracts, presentations, posters) regarding the progress of the project and the preliminary results will be provided to all relevant scientific organisations at European and international level.  Scientific articles of the findings of the clinical trial will be published in (open access) peer reviewed scientific and medical journals.

Publications

Conference proceedings (2)

ADDIA Chronobiology Study and Proof-of-Performance Study to Validate Blood-Based Biomarkers for the Diagnostic of early Alzheimer’s Disease (AD)

Auteurs: F. Blanc, F. Giovanni, M. Marizzoni, C. Mutter, J.C. Bier, F. Sellal, J.F. Démonet, S. Boutillier, H. Firat, S. Moussaoui, R. David, A. Ivanoiu, E. Magnin, A. Gabelle, F. Pasquier, H. Gurvit, B. Dubois
Publié dans: 2019
Éditeur: Alzheimer's and Parkinson's diseases

Addia, a Multi- Center Clinical Study of Proof-of-Performance to Validate Blood-Based Biomarkers for the Diagnostic of Alzheimer’s Disease (AD): The Study Protocol.

Auteurs: Bruno Dubois, MD, PhD, Professor, Jean-Christophe Bier, MD, Frederic Blanc, MD, PhD, Renaud David, MD, PhD, Jean-François Démonet, MD, PhD, Hüseyin Firat, MD, PhD, Giovanni B Frisoni, Prof, PhD, MD, Audrey Gabelle, MD, PhD, Hakan I. Gurvit, MD, Adrian Ivanoiu, MD, PhD, Eloi Magnin, MD, PhD, Moira Marizzoni, PhD, Saliha Moussaoui, PhD, Florence Pasquier, MD PhD and François Sellal, MD
Publié dans: 2018
Éditeur: Alzheimer's Association International Conference

Droits de propriété intellectuelle

Patent (7)

NON-CODING RNAS (NCRNA) FOR THE DIAGNOSIS OF COGNITIVE DISORDERS

Numéro de demande/publication: WO 2019048500
Date: 2017-09-05
Demandeur(s): AMONETA DIAGNOSTICS

DETECTION OF NEURODEGENERATIVE DISEASES

Numéro de demande/publication: EP 17719325
Date: 2017-03-07
Demandeur(s): AMONETA DIAGNOSTICS

Biological complex specific for Alzheimer's disease detection in vitro and use thereof

Numéro de demande/publication: US20130289140 20130289140
Date: 2013-04-30
Demandeur(s): AMONETA DIAGNOSTICS

NOVEL FLUORESCENT BORON-SUBSTITUTED DIPYRROMETHENES AND USE THEREOF FOR DIAGNOSIS

Numéro de demande/publication: EP 09806180
Date: 2009-12-28
Demandeur(s): AMONETA DIAGNOSTICS

DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS

Numéro de demande/publication: EP 09805741
Date: 2009-12-18
Demandeur(s): AMONETA DIAGNOSTICS

Unsaturated dibenzopyrromethene-boron borocarbons

Numéro de demande/publication: WO2006/087458 2006/087458
Date: 2005-02-15
Demandeur(s): AMONETA DIAGNOSTICS

UNSATURATED DIPYRROMETHENE-BORON BOROCARBONS

Numéro de demande/publication: EP 06709313
Date: 2006-02-14
Demandeur(s): AMONETA DIAGNOSTICS